[The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries].

Q4 Medicine
A G Arutyunov, E I Tarlovskaya, G R Galstyan, T I Batluk, R A Bashkinov, G G Arutyunov, Yu N Belenkov, A O Konradi, Yu M Lopatin, A P Rebrov, S N Tereshchenko, A I Chesnikova, H G Hayrapetyan, A P Babin, I G Bakulin, N V Bakulina, L A Balykova, A S Blagonravova, M V Boldina, M I Butomo, A R Vaisberg, A S Galyavich, V V Gomonova, N Yu Grigoryeva, I V Gubareva, I V Demko, A V Evzerikhina, A V Zharkov, A A Zateishchikova, U K Kamilova, Z F Kim, T Yu Kuznetsova, A N Kulikov, N A V Lareva, E V Makarova, S V Malchikova, S V Nedogoda, M M Petrova, I G Pochinka, K V Protasov, D N Protsenko, D Yu Ruzanov, S A Saiganov, A Sh Sarybaev, N M Selezneva, A B Sugraliev, I V Fomin, O V Khlynova, O Yu Chizhova, I I Shaposhnik, D A Schukarev, A K Abdrakhmanova, S A Avetisyan, H G Avoyan, K K Azaryan, G T Aimakhanova, D A Ayypova, A Ch Akunov, M K Alieva, A R Almukhambedova, A V Aparkina, O R Aruslanova, E Yu Ashina, O Na Yu Badina, O Yu Barysheva, A S Batchaeva, A M Bitieva, I U Bikhteev, N A Borodulina, M V Bragin, V A Brazhnik, A M Budu, G A Bykova, K R Vagapova, D D Varlamova, N N Vezikova, E A Verbitskaya, O E Vilkova, E A Vinnikova, V V Vustina, E A Galova, V V Genkel, D B Giller, E I Gorshenina, E V Grigoryeva, E Yu Gubareva, G M Dabylova, A I Demchenko, O Yu Dolgikh, M Y Duishobaev, D S Evdokimov, K E Egorova, A N Ermilova, A E Zheldybaeva, N V Zarechnova, Yu D Zimina, S Yu Ivanova, E Yu Ivanchenko, M V Ilina, M V Kazakovtseva, E V Kazymova, Yu S Kalinina, N A Kamardina, A M Karachenova, I A Karetnikov, N A Karoli, M Kh Karsiev, D S Kaskaeva, K F Kasymova, Zh B Kerimbekova, E S Kim, N V Kiseleva, D A Klimenko, A V Klimova, O V Kovalishena, S V Kozlov, E V Kolmakova, T P Kolchinskaya, M I Kolyadich, O V Kondryakova, M P Konoval, D Yu Konstantinov, E A Konstantinova, V A Kordyukova, E V Koroleva, A Yu Kraposhina, T V Kryukova, A S Kuznetsova, T Yu Kuzmina, K V Kuzmichev, Ch K Kulchoroeva, T V Kuprina, I A M Kuranova, L Va V Kurenkova, N Yu Kurchugina, N A Kushubakova, V I Levankova, A A Ledyaeva, T V Lisun, V E Lisyanskaya, N A Lyubavina, N A Magdeeva, K V Mazalov, V I Mayseenko, A S Makarova, A M Maripov, N V Markov, A A Marusina, E S Melnikov, A I Metlinskaya, N B Moiseenko, F N Muradova, R G Muradyan, Sh N Musaelyan, E S Nekaeva, N M Nikitina, S E Nifontov, E Yu Obolentseva, A A Obukhova, B B Ogurlieva, A A Odegova, Yu V Omarova, N A Omurzakova, Sh O Ospanova, V A Pavlova, E V Pakhomova Pakhomova, L D Petrov, S S Plastinina, D A Platonov, V Aya A Pogrebetskaya, D V Polyakov, D S Polyakov, E Enko V Ponomarenko, L L Popova, A A Potanin, N A Prokofieva, Yu D Rabik, N A Rakov, A N Rakhimov, N A Rozanova, I V Samus, S Serikbolkyzy, Ya A Sidorkina, A A Simonov, V V Skachkova, R D Skvortsova, D S Skuridin, D V Solovieva, I A Solovieva, I M Sukhomlinova, A G Sushilova, D R Tagaeva, Yu V Titoykina, E P Tikhonova, D S Tokmin, A A Tolmacheva, M S Torgunakova, K V Trenogina, N Aya A Trostyanetskaya, D A Trofimov, M A Trubnikova, A A Tulichev, A T Tursunova, N D Ulanova, O V Fatenkov, O V Fedorishina, T S Fil, I Yu Fomina, I S Fominova, I A Frolova, S M Tsvinger, V V Tsoma, M B Cholponbaeva, T Skikh I Chudinovskikh, I V Shavrin, O A Shevchenko, D R Shikhaliev, E A Shishkina, K Yu Shishkov, S Yu Shcherbakov, G V Shcherbakova, E A Yausheva
{"title":"[The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries].","authors":"A G Arutyunov, E I Tarlovskaya, G R Galstyan, T I Batluk, R A Bashkinov, G G Arutyunov, Yu N Belenkov, A O Konradi, Yu M Lopatin, A P Rebrov, S N Tereshchenko, A I Chesnikova, H G Hayrapetyan, A P Babin, I G Bakulin, N V Bakulina, L A Balykova, A S Blagonravova, M V Boldina, M I Butomo, A R Vaisberg, A S Galyavich, V V Gomonova, N Yu Grigoryeva, I V Gubareva, I V Demko, A V Evzerikhina, A V Zharkov, A A Zateishchikova, U K Kamilova, Z F Kim, T Yu Kuznetsova, A N Kulikov, N A V Lareva, E V Makarova, S V Malchikova, S V Nedogoda, M M Petrova, I G Pochinka, K V Protasov, D N Protsenko, D Yu Ruzanov, S A Saiganov, A Sh Sarybaev, N M Selezneva, A B Sugraliev, I V Fomin, O V Khlynova, O Yu Chizhova, I I Shaposhnik, D A Schukarev, A K Abdrakhmanova, S A Avetisyan, H G Avoyan, K K Azaryan, G T Aimakhanova, D A Ayypova, A Ch Akunov, M K Alieva, A R Almukhambedova, A V Aparkina, O R Aruslanova, E Yu Ashina, O Na Yu Badina, O Yu Barysheva, A S Batchaeva, A M Bitieva, I U Bikhteev, N A Borodulina, M V Bragin, V A Brazhnik, A M Budu, G A Bykova, K R Vagapova, D D Varlamova, N N Vezikova, E A Verbitskaya, O E Vilkova, E A Vinnikova, V V Vustina, E A Galova, V V Genkel, D B Giller, E I Gorshenina, E V Grigoryeva, E Yu Gubareva, G M Dabylova, A I Demchenko, O Yu Dolgikh, M Y Duishobaev, D S Evdokimov, K E Egorova, A N Ermilova, A E Zheldybaeva, N V Zarechnova, Yu D Zimina, S Yu Ivanova, E Yu Ivanchenko, M V Ilina, M V Kazakovtseva, E V Kazymova, Yu S Kalinina, N A Kamardina, A M Karachenova, I A Karetnikov, N A Karoli, M Kh Karsiev, D S Kaskaeva, K F Kasymova, Zh B Kerimbekova, E S Kim, N V Kiseleva, D A Klimenko, A V Klimova, O V Kovalishena, S V Kozlov, E V Kolmakova, T P Kolchinskaya, M I Kolyadich, O V Kondryakova, M P Konoval, D Yu Konstantinov, E A Konstantinova, V A Kordyukova, E V Koroleva, A Yu Kraposhina, T V Kryukova, A S Kuznetsova, T Yu Kuzmina, K V Kuzmichev, Ch K Kulchoroeva, T V Kuprina, I A M Kuranova, L Va V Kurenkova, N Yu Kurchugina, N A Kushubakova, V I Levankova, A A Ledyaeva, T V Lisun, V E Lisyanskaya, N A Lyubavina, N A Magdeeva, K V Mazalov, V I Mayseenko, A S Makarova, A M Maripov, N V Markov, A A Marusina, E S Melnikov, A I Metlinskaya, N B Moiseenko, F N Muradova, R G Muradyan, Sh N Musaelyan, E S Nekaeva, N M Nikitina, S E Nifontov, E Yu Obolentseva, A A Obukhova, B B Ogurlieva, A A Odegova, Yu V Omarova, N A Omurzakova, Sh O Ospanova, V A Pavlova, E V Pakhomova Pakhomova, L D Petrov, S S Plastinina, D A Platonov, V Aya A Pogrebetskaya, D V Polyakov, D S Polyakov, E Enko V Ponomarenko, L L Popova, A A Potanin, N A Prokofieva, Yu D Rabik, N A Rakov, A N Rakhimov, N A Rozanova, I V Samus, S Serikbolkyzy, Ya A Sidorkina, A A Simonov, V V Skachkova, R D Skvortsova, D S Skuridin, D V Solovieva, I A Solovieva, I M Sukhomlinova, A G Sushilova, D R Tagaeva, Yu V Titoykina, E P Tikhonova, D S Tokmin, A A Tolmacheva, M S Torgunakova, K V Trenogina, N Aya A Trostyanetskaya, D A Trofimov, M A Trubnikova, A A Tulichev, A T Tursunova, N D Ulanova, O V Fatenkov, O V Fedorishina, T S Fil, I Yu Fomina, I S Fominova, I A Frolova, S M Tsvinger, V V Tsoma, M B Cholponbaeva, T Skikh I Chudinovskikh, I V Shavrin, O A Shevchenko, D R Shikhaliev, E A Shishkina, K Yu Shishkov, S Yu Shcherbakov, G V Shcherbakova, E A Yausheva","doi":"10.14341/probl13165","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).</p><p><strong>Aim: </strong>To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.</p><p><strong>Materials and methods: </strong>AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected  the  data  of  hospitalized  patients  and  included  3  visits.  All  subjects  were  divided  into  3  groups:  not  overweight  (n=2139), overweight (n=2931) and obese (n=2666).</p><p><strong>Results: </strong>A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (p&lt;0.001), serum C-reactive protein over 100 mg/l (p&lt;0.001), and the need for targeted therapy (p&lt;0.001) in the hospitalized patients. Obesity increased the odds of myocarditis by 1,84 times (95% confidence interval [CI]: 1,13-3,00) and the need for anticytokine therapy by 1,7 times (95% CI: 1,30-2,30).The  patients  with  the  1st  and  2nd  degree  obesity,  undergoing  the  inpatient  treatment,  tended  to  have  a  higher  probability  of  a  mortality  rate.  While  in  case  of  morbid  obesity  patients  this  tendency  is  the  most  significant  (odds  ratio  -  1,78; 95% CI: 1,13-2,70). At the same time, the patients whose chronical diseases first appeared after the convalescence period, and those who had certain complaints missing before SARS-CoV-2 infection, more often had BMI of more than 30 kg/m2 (p&lt;0,001).Additionally, the odds of death increased by 2,23 times (95% CI: 1,05-4,72) within 3 months after recovery in obese people over the age of 60 yearsCONCLUSION.  Overweight  and/or  obesity  is  a  significant  risk  factor  for severe  course  of  the  new  coronavirus  infection  and  the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.</p>","PeriodicalId":20433,"journal":{"name":"Problemy endokrinologii","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939974/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problemy endokrinologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/probl13165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).

Aim: To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.

Materials and methods: AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected  the  data  of  hospitalized  patients  and  included  3  visits.  All  subjects  were  divided  into  3  groups:  not  overweight  (n=2139), overweight (n=2931) and obese (n=2666).

Results: A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (p<0.001), serum C-reactive protein over 100 mg/l (p<0.001), and the need for targeted therapy (p<0.001) in the hospitalized patients. Obesity increased the odds of myocarditis by 1,84 times (95% confidence interval [CI]: 1,13-3,00) and the need for anticytokine therapy by 1,7 times (95% CI: 1,30-2,30).The  patients  with  the  1st  and  2nd  degree  obesity,  undergoing  the  inpatient  treatment,  tended  to  have  a  higher  probability  of  a  mortality  rate.  While  in  case  of  morbid  obesity  patients  this  tendency  is  the  most  significant  (odds  ratio  -  1,78; 95% CI: 1,13-2,70). At the same time, the patients whose chronical diseases first appeared after the convalescence period, and those who had certain complaints missing before SARS-CoV-2 infection, more often had BMI of more than 30 kg/m2 (p<0,001).Additionally, the odds of death increased by 2,23 times (95% CI: 1,05-4,72) within 3 months after recovery in obese people over the age of 60 yearsCONCLUSION.  Overweight  and/or  obesity  is  a  significant  risk  factor  for severe  course  of  the  new  coronavirus  infection  and  the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.

Abstract Image

Abstract Image

Abstract Image

[体重指数对急性 SARS-COV-2 感染过程的影响以及出院后第一年出现的风险。AKTIV 和 AKTIV 2 登记的子分析证据]。
背景:有足够的证据表明,超重对呼吸道病变的形成和发展有负面影响。鉴于 SARS-CoV-2 大流行仍在继续,确定体重指数(BMI)与新型冠状病毒感染(NCI)临床特征之间的关系具有重要意义:AKTIV 和 AKTIV 2 是多中心非干预性真实世界登记。АКТИВ登记处(n=6396)包括不重叠的门诊和住院两部分,每部分有 6 次就诊机会。АКТИВ 2登记处(人数=2968)收集了住院患者的数据,包括3次就诊。 所有受试者被分为三组:未超重组(2139 人)、超重组(2931 人)和肥胖组(2666 人):结果:在住院患者中,体重指数越高,感染过程越严重,表现为急性肾损伤(p=0.018)、细胞因子风暴(p<0.001)、血清 C 反应蛋白超过 100 毫克/升(p<0.001)以及需要针对性治疗(p<0.001)。肥胖使心肌炎的发病几率增加了 1.84 倍(95% 置信区间 [CI]:1.13-3.00),需要抗细胞因子治疗的几率增加了 1.7 倍(95% 置信区间 [CI]:1.30-2.30)。 而病态肥胖症患者的这一趋势最为明显(几率比-1.78;95% CI:1.13-2.70)。此外,60 岁以上的肥胖者在康复后 3 个月内死亡的几率增加了 2.23 倍(95% CI:1.05-4.72)。 超重和/或肥胖是导致新型冠状病毒感染病情恶化以及相关心血管和肾脏损害的重要危险因素 超重人群以及一等和二等肥胖症患者在感染 SARS-CoV-2 后的急性期和后期死亡风险都很高。此外,病态肥胖患者的这一趋势在统计学上具有显著意义。体重正常化是现代医学的一个战略目标,有助于预防呼吸系统疾病、严重病程和新型冠状病毒感染并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Problemy endokrinologii
Problemy endokrinologii Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
1.40
自引率
0.00%
发文量
59
期刊介绍: Since 1955 the “Problems of Endocrinology” (or “Problemy Endocrinologii”) Journal publishes timely articles, balancing both clinical and experimental research, case reports, reviews and lectures on pressing problems of endocrinology. The Journal is aimed to the most topical issues of endocrinology: to chemical structure, biosynthesis and metabolism of hormones, the mechanism of their action at cellular and molecular level; pathogenesis and to clinic of the endocrine diseases, new methods of their diagnostics and treatment. The Journal: features original national and foreign research articles, reflecting world endocrinology development; issues thematic editions on specific areas; publishes chronicle of major international congress sessions and workshops on endocrinology, as well as state-of-the-art guidelines; is intended for scientists, endocrinologists diabetologists and specialists of allied trade, general practitioners, family physicians and pediatrics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信